Alkermes plc (ALKS) lost 10.51% on Thursday, after Jefferies analyst Biren Amin downgraded the stock from Buy to Hold with a price target of $66.00. There are a couple of clinical and regulatory catalysts related to Alkermes to keep an eye on in the coming months.
from RTT - Biotech http://ift.tt/2FrSR64
via IFTTT
No comments:
Post a Comment